GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Mechanisms and therapeutic implications of temozolomide resistance in glioblastoma

$76,052
Matthew McCord · Northwestern University At Chicago · F32 · FY2023 · CA

Dual targeting of cGAS-STING and splicing to prime lung cancer immunogenicity

$76,052
Patrick C Gedeon · Brigham And Women'S Hospital · F32 · FY2023 · CA

Functional study of C53 protein as a novel regulator of checkpoint kinases

$75,990
Honglin Li · Augusta University · R01 · FY2010 · GM

Mitotic Mechanisms in Alzheimer's Disease

$75,800
University Of Washington · R01 · FY2005 · AG

Improvement of cellular immunotherapy during dysbiosis- Resubmission

$75,787
Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA

Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression

$75,660
Anil Shanker · Meharry Medical College · U54 · FY2020 · CA

Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression

$75,660
Anil Shanker · Meharry Medical College · U54 · FY2016 · CA

Immune Regulation of Disseminated Cancer Cell Dormancy

$75,600
Julio A Aguirre-Ghiso · Albert Einstein College Of Medicine · R03 · FY2022 · CA

Impact of LAG3 on CD8+ T cell motility and migration in the context of cancer immunotherapy

$75,520
Andrew Stephen Baessler · University Of Pittsburgh At Pittsburgh · F32 · FY2025 · CA

Evaluate the Role and Mechanism of GPR4 in Immunotherapy-Related Colitis

$75,500
Li Yang · East Carolina University · R03 · FY2022 · CA

Evaluate the Role and Mechanism of GPR4 in Immunotherapy-Related Colitis

$75,500
Li Yang · East Carolina University · R03 · FY2023 · CA

Investigating the hnRNPA18-HIF-1a axis in solid tumors

$75,447
France Carrier · University Of Maryland Baltimore · R01 · FY2024 · CA

Mitochondrial dynamics in human pulmonary hypertension: a new therapeutic target

$75,208
Willard William Sharp · University Of Chicago · R03 · FY2013 · HL

Validation of new biomarker for human cancers

$75,000
University Of Texas Md Anderson Can Ctr · R03 · FY2005 · CA

Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer

$74,947
Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2022 · CA

Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC

$74,886
Chendi Li · Massachusetts General Hospital · F32 · FY2021 · CA

Program 4: Leukemia

$74,826
David Marc Weinstock · Dana-Farber Cancer Inst · P30 · FY2021 · CA

Immunomodulation by dietary protein restriction

$74,791
Roberto Pili · Indiana University Indianapolis · R21 · FY2019 · CA

Program 4: Leukemia

$74,713
David Marc Weinstock · Dana-Farber Cancer Inst · P30 · FY2020 · CA

Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response

$74,545
Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2023 · CA

Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer

$74,509
Meghan E. Sise · Massachusetts General Hospital · R01 · FY2023 · DK

Molecular mechanisms of genome maintenance during DNA replication and repair

$74,466
Kamakoti P. Bhat · Stanford University · K00 · FY2018 · CA

Tumor-derived Exosome Induction of Dendritic Cell Tolerization

$74,292
Michael Paul Plebanek · Duke University · F32 · FY2023 · CA

Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression

$74,288
Anil Shanker · Meharry Medical College · U54 · FY2017 · CA

Metabolites regulating macrophage function in colorectal cancer

$74,274
Subbaya Subramanian · University Of Minnesota · R03 · FY2023 · CA